In-Person Access Only | 4.50 CME Credits
Please read: All programs remain free. Registrations will require a credit card as a cancellation hold. A fee of $99 will only be incurred in the event of a no-show or cancellation within 5 days without written confirmation to the Total Health Program Team. Industry representatives—defined as any individual who is employed by, contracted with, owns, or represents a drug, device, diagnostic, or other healthcare-related commercial entity, regardless of clinical credentials or licensure—are not permitted to attend Total Health events as general attendees. Members of industry must contact exhibits@totalhealthoncology.com
The First Annual DEBATING BREAST CANCER Symposium will take place January 22–23, 2027, in San Francisco, California. This first-of-its-kind educational forum brings together internationally recognized breast cancer experts for a series of engaging, evidence-based debates addressing the most controversial and practice-changing questions in breast oncology. Covering early-stage disease, metastatic breast cancer, and emerging future directions, faculty will present opposing viewpoints on evolving standards of care, novel therapeutics, biomarker-driven treatment strategies, clinical trial design, and the integration of cutting-edge technologies such as ctDNA and artificial intelligence. Designed to challenge conventional thinking and encourage thoughtful discussion, the symposium provides attendees with balanced perspectives, practical clinical insights, and actionable strategies to navigate the rapidly evolving breast cancer treatment landscape.
Conference Agenda
Friday, January 22, 2027
Program Chairs:
TBD
3:00 - 4:00 PM
Arrival, Networking, and Registration
4:00 - 5:30 PM
Breakout Focus Groups
5:30 - 6:30 PM
Networking Reception
7:00 - 9:00 PM
Faculty Dinner
Saturday, January 23, 2027
7:30 - 8:30 AM
Arrival, Breakfast, and Registration
8:30 - 8:45 AM
Welcome and Opening Remarks
8:45 - 10:15 AM
Early Stage Breast Debate
CDK4/6 Inhibitors in Early HR+/HER2− Disease: New Standard or Selective Use?
ctDNA in Early Breast Cancer: Ready for Clinical Prime Time?
Adjuvant therapy for Triple Negative Breast Cancer patients who achieve pathologic CR after neoadjuvant therapy
10:15 - 10:30 AM
Breakfast & Exhibits
10:30 AM - 12:00 PM
Advanced Stage Breast Debate
ADCs vs Chemotherapy: Has Conventional Chemotherapy Become Obsolete?
Comprehensive NGS for Every Metastatic Patient?
Sequencing in HR+/HER2− Disease: Are CDK4/6 Inhibitors Still the Center of the Universe?
12:00 - 12:45 PM
Lunch & Exhibits
12:45 - 1:45 PM
Future Directions in Breast Debate
Will ctDNA Replace Imaging in Surveillance?
The Future of Clinical Trials: AI enabled
1:45 - 3:30 PM
Breakout Focus Groups
3:30 PM
ADJOURN
Agenda Subject To Change. All times are PST.
-
-
-
Complimentary registration for healthcare professionals
Evidence-based debates featuring internationally recognized breast cancer experts
Balanced perspectives on today's most controversial clinical questions
Practical strategies to help translate emerging evidence into clinical practice
Interactive discussion and networking with leading clinicians and peers
Access to the latest research, therapeutic advances, and industry innovations